FR2622192B1 - - Google Patents

Info

Publication number
FR2622192B1
FR2622192B1 FR8813812A FR8813812A FR2622192B1 FR 2622192 B1 FR2622192 B1 FR 2622192B1 FR 8813812 A FR8813812 A FR 8813812A FR 8813812 A FR8813812 A FR 8813812A FR 2622192 B1 FR2622192 B1 FR 2622192B1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR8813812A
Other languages
French (fr)
Other versions
FR2622192A1 (fr
Inventor
Edgar E Ribi
Kent R Myers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ribi Immunochem Research Inc
Original Assignee
Ribi Immunochem Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribi Immunochem Research Inc filed Critical Ribi Immunochem Research Inc
Publication of FR2622192A1 publication Critical patent/FR2622192A1/fr
Application granted granted Critical
Publication of FR2622192B1 publication Critical patent/FR2622192B1/fr
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C07H13/06—Fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/06—Peptides being immobilised on, or in, an organic carrier attached to the carrier via a bridging agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
FR8813812A 1987-10-22 1988-10-21 Derives de lipide monophosphoryle a et leur procede de preparation Granted FR2622192A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/112,742 US4987237A (en) 1983-08-26 1987-10-22 Derivatives of monophosphoryl lipid A

Publications (2)

Publication Number Publication Date
FR2622192A1 FR2622192A1 (fr) 1989-04-28
FR2622192B1 true FR2622192B1 (Direct) 1994-11-10

Family

ID=22345625

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8813812A Granted FR2622192A1 (fr) 1987-10-22 1988-10-21 Derives de lipide monophosphoryle a et leur procede de preparation

Country Status (10)

Country Link
US (1) US4987237A (Direct)
JP (1) JPH075623B2 (Direct)
BE (1) BE1003250A5 (Direct)
CA (1) CA1308711C (Direct)
CH (1) CH676715A5 (Direct)
DE (1) DE3836006C2 (Direct)
FR (1) FR2622192A1 (Direct)
GB (1) GB2211502B (Direct)
IT (1) IT1230592B (Direct)
NL (1) NL8802595A (Direct)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158939A (en) * 1989-07-21 1992-10-27 Wisconsin Alumni Research Foundation Method of stimulating the immune systems of animals and compositions useful therefor
FI920131A0 (fi) * 1989-07-14 1992-01-13 Praxis Biolog Inc Cytokin- och hormonbaerare foer konjugatvaccin.
US5498708A (en) * 1989-07-18 1996-03-12 Montefiore Medical Center Method of synthesizing polyesters
US5278300A (en) * 1990-04-12 1994-01-11 Japan Tobacco, Inc. 4,6-o-hydroxyphosphoryl-glucosamine derivatives
US5653974A (en) * 1990-10-18 1997-08-05 Board Of Regents,The University Of Texas System Preparation and characterization of liposomal formulations of tumor necrosis factor
US5164375A (en) * 1991-09-27 1992-11-17 Merck & Company, Inc. Antifungal agent
US5648343A (en) * 1994-02-28 1997-07-15 The University Of Georgia Research Foundation Method for treating LPS-mediated disorders
US6218166B1 (en) 1994-12-09 2001-04-17 John Wayne Cancer Institute Adjuvant incorporation into antigen carrying cells: compositions and methods
US5750664A (en) * 1995-06-05 1998-05-12 Eisai Co., Ltd. Substituted liposaccharides useful in the treatment and prevention of endotoxemia
US6290971B1 (en) * 1995-06-15 2001-09-18 Aventis Pasteur Limited Adjuvant compositions comprising a mineral salt and another immunostimulating compound
GB9706957D0 (en) * 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
GB0000891D0 (en) * 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US20030139356A1 (en) 2001-05-18 2003-07-24 Persing David H. Prophylactic and therapeutic treatment of infectious and other diseases with mono- and disaccharide-based compounds
PL206832B1 (pl) 2000-05-19 2010-09-30 Corixa Corp Zastosowanie związków opartych na mono- i disacharydach
US20030138769A1 (en) * 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
US20030185858A1 (en) * 2001-08-15 2003-10-02 Birkett Ashley J. Immunogenic HBc chimer particles stabilized with an N-terminal cysteine
US7361352B2 (en) * 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
US20030175863A1 (en) * 2001-08-15 2003-09-18 Birkett Ashley J. Influenza immunogen and vaccine
JP2005516980A (ja) * 2002-02-04 2005-06-09 コリクサ コーポレイション 新規な免疫エフェクター化合物
US6911434B2 (en) * 2002-02-04 2005-06-28 Corixa Corporation Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
US20040033213A1 (en) * 2002-02-28 2004-02-19 Corixa Corporation Methods of modulating dendritic cells using adjuvants
US20030224013A1 (en) * 2002-04-19 2003-12-04 Cole Garry T. Methods for protection against Coccidioides spp. infection using Coccidioides spp. urea amidohydrolase (Ure) protein
EP1521762B1 (en) 2002-07-08 2014-03-12 Corixa Corporation Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor
EP1589934B1 (en) 2003-01-06 2015-09-23 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
DK1449535T3 (da) * 2003-02-18 2006-09-11 Clinique La Prairie Res Sa Præparater der omfatter fötalt hæmoglobin og bakterieendotoksin samt eventuelt fötale leverbestanddele
EP1835935A4 (en) * 2004-12-30 2009-06-17 Univ Rockefeller COMPOSITIONS AND METHODS FOR ENHANCING THE MATURATION AND FUNCTION OF DENDRITIC CELLS
US20060210590A1 (en) 2005-02-03 2006-09-21 Alk-Abello A/S Minor allergen control to increase safety of immunotherapy
US7622128B2 (en) * 2005-12-13 2009-11-24 University Of Washington Porphyromonas gingivalis 1435/1449 LPS as an immune modulator
HUE036180T2 (hu) 2006-09-26 2018-06-28 Infectious Disease Res Inst Szintetikus adjuvánst tartalmazó vakcina készítmény
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
AU2008281384C1 (en) 2007-08-02 2012-08-16 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope influenza vaccines
US20090215710A1 (en) * 2007-09-24 2009-08-27 Reliance Life Sciences Pvt. Ltd. Carbohydrate based toll-like receptor (tlr) antagonists
US20090215908A1 (en) * 2007-09-24 2009-08-27 Reliance Life Sciences Pvt. Ltd. Toll like receptor (tlr) signaling antagonist
AU2008331800A1 (en) 2007-12-03 2009-06-11 President And Fellows Of Harvard College Chlamydia antigens
PL2437753T3 (pl) 2009-06-05 2017-03-31 Infectious Disease Research Institute Syntetyczne adiuwanty glukopiranozylolipidowe oraz zawierające je kompozycje szczepionek
AU2011360572B2 (en) 2011-02-22 2017-03-02 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
AU2012243039B2 (en) 2011-04-08 2017-07-13 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
GB201106802D0 (en) 2011-04-21 2011-06-01 Allergy Therapeutics Ltd Process for preparing vaccine composition
NZ701881A (en) 2012-05-16 2016-10-28 Immune Design Corp Vaccines for hsv-2
US11576958B2 (en) 2013-02-07 2023-02-14 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
EP2958935B1 (en) 2013-02-20 2019-07-03 Bergen Teknologioverforing AS Vaccine
EA032326B1 (ru) 2013-04-18 2019-05-31 Иммьюн Дизайн Корп. Монотерапия gla для применения в лечении рака
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
EP3632458B1 (en) 2013-07-26 2025-03-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of bacterial infections
WO2016180852A1 (en) 2015-05-12 2016-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preparing antigen-specific t cells from an umbilical cord blood sample
US11524069B2 (en) 2017-09-13 2022-12-13 Sanofi Pasteur Human cytomegalovirus immunogenic composition
TW202003023A (zh) 2018-03-12 2020-01-16 美商詹森藥物公司 針對尿路感染之疫苗
US20220249644A1 (en) 2018-08-24 2022-08-11 Vestlandets Innovasjonsselskap As (Vis) Heat-Stable Enterotoxins Mutants as Antidiarrheal Vaccine Antigens
WO2021067785A1 (en) 2019-10-02 2021-04-08 Janssen Vaccines & Prevention B.V Staphylococcus peptides and methods of use
PL4090363T3 (pl) 2020-01-16 2024-11-25 Janssen Pharmaceuticals, Inc. Mutant fimh, jego kompozycje i jego zastosowanie
MX2023008251A (es) 2021-01-12 2023-07-26 Janssen Pharmaceuticals Inc Mutantes de fimh, composiciones con estos y uso de estos.
US12290563B2 (en) 2021-04-01 2025-05-06 Janssen Pharmaceuticals, Inc. Production of E. coli 018 bioconjugates

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0414725Y2 (Direct) * 1980-09-30 1992-04-02
US4436728A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4436727A (en) * 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
JPS62129293A (ja) * 1985-11-28 1987-06-11 Toho Yakuhin Kogyo Kk 親水性のリピドａ単糖類縁体
JPS62195396A (ja) * 1986-02-20 1987-08-28 Toho Yakuhin Kogyo Kk 親水性及び疎水性の基を置換したりピドａ単糖類縁体

Also Published As

Publication number Publication date
JPH075623B1 (Direct) 1995-01-25
DE3836006C2 (de) 1996-07-11
GB8824330D0 (en) 1988-11-23
IT1230592B (it) 1991-10-28
JPH075623B2 (ja) 1995-01-25
CA1308711C (en) 1992-10-13
GB2211502A (en) 1989-07-05
JPH01146891A (ja) 1989-06-08
DE3836006A1 (de) 1989-05-03
FR2622192A1 (fr) 1989-04-28
US4987237A (en) 1991-01-22
CH676715A5 (Direct) 1991-02-28
BE1003250A5 (fr) 1992-02-11
NL8802595A (nl) 1989-05-16
GB2211502B (en) 1992-02-19
IT8822399A0 (it) 1988-10-21

Similar Documents

Publication Publication Date Title
FR2622192B1 (Direct)
AU632031B2 (Direct)
AU5525386A (Direct)
AU5597786A (Direct)
AU5648086A (Direct)
AU5874486A (Direct)
AU6245986A (Direct)
AU6268886A (Direct)
AU6445686A (Direct)
AU6448286A (Direct)
AU7537187A (Direct)
AU7945287A (Direct)
AU7986487A (Direct)
BG44567A1 (Direct)
BG44590A1 (Direct)
BG44597A1 (Direct)
BG44601A1 (Direct)
BG44627A1 (Direct)
BG44631A1 (Direct)
BG44642A1 (Direct)
BG44647A1 (Direct)
BG44669A1 (Direct)
BG44714A1 (Direct)
BG44742A1 (Direct)
BG44750A1 (Direct)